Logo image of SLRX

SALARIUS PHARMACEUTICALS INC (SLRX) Stock Overview

NASDAQ:SLRX - US79400X4043 - Common Stock

5.77 USD
+0.45 (+8.46%)
Last: 8/22/2025, 8:00:02 PM

SLRX Key Statistics, Chart & Performance

Key Statistics
52 Week High108
52 Week Low4.76
Market Cap44.14M
Shares7.65M
Float7.63M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-23.95
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12/amc
IPO01-29 2015-01-29
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


SLRX short term performance overview.The bars show the price performance of SLRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

SLRX long term performance overview.The bars show the price performance of SLRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SLRX is 5.77 USD. In the past month the price decreased by -48.71%. In the past year, price decreased by -79.32%.

SALARIUS PHARMACEUTICALS INC / SLRX Daily stock chart

SLRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.89 372.04B
AMGN AMGEN INC 13.47 158.13B
GILD GILEAD SCIENCES INC 14.83 142.41B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.30B
REGN REGENERON PHARMACEUTICALS 12.92 62.48B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.56B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 6.35 37.29B
INSM INSMED INC N/A 27.88B
BNTX BIONTECH SE-ADR N/A 26.66B
NTRA NATERA INC N/A 22.73B
BIIB BIOGEN INC 8.7 20.42B

About SLRX

Company Profile

SLRX logo image Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.

Company Info

SALARIUS PHARMACEUTICALS INC

2450 Holcombe Blvd Ste J-608

Houston TEXAS 77021 US

CEO: David J. Arthur

Employees: 2

SLRX Company Website

SLRX Investor Relations

Phone: 13467720346

SALARIUS PHARMACEUTICALS INC / SLRX FAQ

What is the stock price of SALARIUS PHARMACEUTICALS INC today?

The current stock price of SLRX is 5.77 USD. The price increased by 8.46% in the last trading session.


What is the ticker symbol for SALARIUS PHARMACEUTICALS INC stock?

The exchange symbol of SALARIUS PHARMACEUTICALS INC is SLRX and it is listed on the Nasdaq exchange.


On which exchange is SLRX stock listed?

SLRX stock is listed on the Nasdaq exchange.


What is SALARIUS PHARMACEUTICALS INC worth?

SALARIUS PHARMACEUTICALS INC (SLRX) has a market capitalization of 44.14M USD. This makes SLRX a Nano Cap stock.


How many employees does SALARIUS PHARMACEUTICALS INC have?

SALARIUS PHARMACEUTICALS INC (SLRX) currently has 2 employees.


What are the support and resistance levels for SALARIUS PHARMACEUTICALS INC (SLRX) stock?

SALARIUS PHARMACEUTICALS INC (SLRX) has a resistance level at 7.8. Check the full technical report for a detailed analysis of SLRX support and resistance levels.


Should I buy SALARIUS PHARMACEUTICALS INC (SLRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SALARIUS PHARMACEUTICALS INC (SLRX) stock pay dividends?

SLRX does not pay a dividend.


When does SALARIUS PHARMACEUTICALS INC (SLRX) report earnings?

SALARIUS PHARMACEUTICALS INC (SLRX) will report earnings on 2025-11-12, after the market close.


What is the Price/Earnings (PE) ratio of SALARIUS PHARMACEUTICALS INC (SLRX)?

SALARIUS PHARMACEUTICALS INC (SLRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-23.95).


SLRX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SLRX Financial Highlights

Over the last trailing twelve months SLRX reported a non-GAAP Earnings per Share(EPS) of -23.95. The EPS decreased by -89.46% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -366.41%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-185.55%
Sales Q2Q%N/A
EPS 1Y (TTM)-89.46%
Revenue 1Y (TTM)N/A

SLRX Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y-126.98%
Revenue Next YearN/A

SLRX Ownership

Ownership
Inst Owners3.29%
Ins Owners1.71%
Short Float %N/A
Short Ratio0.2